Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 13, 2023 4:37pm

131 Views

Post# 35634720

RE:RE:RE:RE:A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

Well I suppose they did mention the US$17.5 million stock purhcase but here is their assessment and no mention of PanCan.

At this burn rate, with the extra money in the tank, this means that ONCY will be able to sustain operations for 5 to 6 more quarters.

And yes, for pancreatic cancer a 69% response rate not only sounds but is great, which is why PanCan selected ONCYs pelareorep for its Precision Promise clinical trial program, and not the ghost writer from SeekingAlpha.

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter